On 27 October 2011, orphan designation (EU/3/11/916) was granted by the European Commission to Lipopharma Therapeutics SL, Spain, for 2-hydroxyoleic acid for the treatment of glioma.
In February 2020, Lipopharma Therapeutics SL changed name to Laminar Pharmaceuticals S.L.
|Disease / condition||
Treatment of glioma
|Date of first decision||
|EU designation number||
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
Laminar Pharmaceuticals S.L.
Ctra. de Valldemossa Km. 7,4 – ParcBIT
Incubadora de Empresas de Base Tecnológica
Edificio 17, 2n, Mod. C-8
E07121 - Palma de Mallorca
Tel.: +34 97 143 9886
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.